Highest-materiality recent filing
Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman
Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026
Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001
Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.
CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora
Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors
Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML
Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance
Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.
6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.
Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease
Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.
Galecto receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure
Nasdaq notified Galecto that common stock bid price closed below $1.00 for 30 consecutive business days.
Galecto explores strategic alternatives; cuts workforce 70%, CMO out
Workforce reduction of ~29 employees (~70% of headcount) approved Sept 20, 2023.
Galecto's Phase 2b GALACTIC-1 trial misses primary endpoint; GB0139 discontinued
GALACTIC-1 trial did not meet primary endpoint of FVC decline; change from baseline -316.6 mL vs -127.4 mL (placebo).
Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD
GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.
Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients
Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.
Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.
the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.
the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.
appointed Amy Wechsler to join the Board, effective as of October 11, 2024.
on September 21, 2023, the Company informed Bertil Lindmark, M.D., the Company’s Chief Medical Officer, that his position will be eliminated and that his duties will be assumed by Hans Schambye, M.D., Ph.D., the Company’s Chief Executive Officer.
Max materiality 0.90 · Median 0.55 · Most common event other_material